Distinguished in Aplastic Anemia

Dr. Hugo R. Castro-Malaspina

Hematology
1275 York Ave, 
New York, NY 
50 Years of Experience
Distinguished in Aplastic Anemia
1275 York Ave, 
New York, NY 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Hugo Castro-Malaspina is a Hematologist in New York, New York. Dr. Castro-Malaspina has been practicing medicine for over 50 years and is rated as a Distinguished provider by MediFind in the treatment of Aplastic Anemia. His top areas of expertise are Myelodysplastic Syndrome (MDS), Graft Versus Host Disease (GvHD), Acute Myeloid Leukemia (AML), Aplastic Anemia, and Bone Marrow Transplant.

His clinical research consists of co-authoring 62 peer reviewed articles and participating in 2 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 2 articles in the study of Aplastic Anemia.

Specialties
Hematology
Licenses
Internal Medicine in NY
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO

Locations

1275 York Ave, New York, NY 10021

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

2 Clinical Trials

A Phase II Trial of Busulfan, Melphalan, and Fludarabine With Peri-transplant Palifermin, Followed by a T-Cell Depleted Hematopoietic Stem Cell Transplant From HLA Matched or Mismatched Related or Unrelated Donors in Patients With Advanced Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML)
A Phase II Trial of Busulfan, Melphalan, and Fludarabine With Peri-transplant Palifermin, Followed by a T-Cell Depleted Hematopoietic Stem Cell Transplant From HLA Matched or Mismatched Related or Unrelated Donors in Patients With Advanced Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML)
Enrollment Status: Completed
Publish Date: September 24, 2021
Intervention Type: Drug
Study Phase: Phase 2
An Open-label, Multi-center, Expanded Treatment Protocol of Midostaurin (PKC412) in Adult Patients With Newly Diagnosed Fms-like Tyrosine Kinase Receptor (FLT3) Mutated Acute Myeloid Leukemia (AML) Who Are Eligible for Standard Induction and Consolidation Chemotherapy.
An Open-label, Multi-center, Expanded Treatment Protocol of Midostaurin (PKC412) in Adult Patients With Newly Diagnosed Fms-like Tyrosine Kinase Receptor (FLT3) Mutated Acute Myeloid Leukemia (AML) Who Are Eligible for Standard Induction and Consolidation Chemotherapy.
Enrollment Status: No_longer_available
Publish Date: July 15, 2020
Intervention Type: Drug
View 1 Less Clinical Trial

62 Total Publications

Third-party cytomegalovirus-specific T cells improved survival in refractory cytomegalovirus viremia after hematopoietic transplant.
Third-party cytomegalovirus-specific T cells improved survival in refractory cytomegalovirus viremia after hematopoietic transplant.
Journal: The Journal of clinical investigation
Published: September 16, 2022
Similar Doctors
Distinguished in Aplastic Anemia
Dr. Jamie L. Koprivnikar
Oncology | Hematology
Distinguished in Aplastic Anemia
Dr. Jamie L. Koprivnikar
Oncology | Hematology

Regional Cancer Care Associates LLC

30 Prospect Ave, 
Hackensack, NJ 
 (9.8 miles away)
201-996-2210
Languages Spoken:
English
See accepted insurances

Jamie Koprivnikar is an Oncologist and a Hematologist in Hackensack, New Jersey. Dr. Koprivnikar is rated as a Distinguished provider by MediFind in the treatment of Aplastic Anemia. Her top areas of expertise are Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS), Acute Myeloblastic Leukemia without Maturation, Bone Marrow Aspiration, and Endoscopy.

David J. Araten
Distinguished in Aplastic Anemia
Dr. David J. Araten
Hematology Oncology | Hematology | Oncology
Distinguished in Aplastic Anemia
Dr. David J. Araten
Hematology Oncology | Hematology | Oncology

New York University

111 Broadway, 
New York, NY 
 (4.8 miles away)
212-263-9700
Languages Spoken:
English
See accepted insurances

David Araten is a Hematologist Oncology specialist and a Hematologist in New York, New York. Dr. Araten is rated as a Distinguished provider by MediFind in the treatment of Aplastic Anemia. His top areas of expertise are Paroxysmal Nocturnal Hemoglobinuria (PNH), Paroxysmal Cold Hemoglobinuria, Aplastic Anemia, Hemolytic Anemia, and Bone Marrow Aspiration.

Distinguished in Aplastic Anemia
Dr. Katherine Linder
Hematology | Oncology
Distinguished in Aplastic Anemia
Dr. Katherine Linder
Hematology | Oncology

Regional Cancer Care Associates LLC

92 2nd St, 
Hackensack, NJ 
 (9.8 miles away)
201-996-5900
Languages Spoken:
English
See accepted insurances

Katherine Linder is a Hematologist and an Oncologist in Hackensack, New Jersey. Dr. Linder is rated as a Distinguished provider by MediFind in the treatment of Aplastic Anemia. Her top areas of expertise are Myelodysplastic Syndrome (MDS), Acute Myeloid Leukemia (AML), Aplastic Anemia, Acute Myeloblastic Leukemia without Maturation, and Bone Marrow Aspiration.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Castro-Malaspina's expertise for a condition
ConditionClose
View All 32 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile